Werewolf Therapeutics’ Clinical Data for WTX-124 and WTX-330 Presented at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting

Werewolf Therapeutics, Inc. (HOWL) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Werewolf Therapeutics’ Clinical Data for WTX-124 and WTX-330 Presented at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting – In a Phase 1/1b clinical trial , WTX-124 was administered safely at its recommended Phase 2 dose of 18 mg IV Q2W in the ou

Event · Clinical / regulatory
Product
WTX-124
Milestone
topline data
Indication
relapsed/refractory immunotherapy-sensitive solid tumors

Facts are quoted from the filing text and checked against it.

Original reporting
Published Nov 9, 2026, 2:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 2:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$HOWL
Bullish
high confidence
Mentioned
$HOWL
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$HOWLBullishMed
01

Why it matters

The disclosed data suggest safety and efficacy, potentially de‑risking the programs and supporting future financing or partnership opportunities.

02

Market read

First‑time disclosure of early clinical data for a micro‑cap biotech; could trigger short‑term price movement and longer‑term valuation shifts.

03

What to watch

Small patient cohorts and lack of long‑term survival data could limit the impact.

Relevance 8/10Novelty 8/10Timing: today

Background

Werewolf Therapeutics (NASDAQ: HOWL) announced Phase 1/1b results for WTX-124 and Phase 1b/2 results for WTX-330 at the Society for Immunotherapy of Cancer's 2026 annual meeting.

Company-level read

Ticker impact

$HOWLBullishHigh confidence
Context

Werewolf Therapeutics disclosed new Phase 1/1b data for WTX-124 and Phase 1b/2 data for WTX-330 at the SITC 2026 meeting.

Expected impact

upward pressure as investors price in promising early‑stage data.

Evidence & confidence

The data show durable responses and manageable safety, which are material for a micro‑cap biotech and may trigger buying interest.

Market effects

Early‑stage IL‑2/IL‑12 IND‑UKINE data could boost sentiment in the immunotherapy and broader biotech sector.

US biotech market may see modest buying pressure.

Limited to investors tracking early‑stage oncology pipelines.

Counterpoint

Early data may not translate to later‑stage trials; investors should be cautious of over‑optimism.

Key entities

  • Werewolf Therapeutics

    Biopharma developing conditionally activated IL‑2 and IL‑12 therapeutics.

  • WTX-124

    Conditionally activated IL‑2 prodrug showing responses in solid tumors.

  • WTX-330

    Conditionally activated IL‑12 prodrug with early activity signals.

Related articles

$HOWLHighAI 8/10

Werewolf Therapeutics And Ambros Therapeutics Announce Merger; Secure $150M Financing

Werewolf Therapeutics (HOWL) and Ambros Therapeutics announced an all-stock merger, creating a Nasdaq-listed biotech firm focused on neridronate for CRPS-1. The combined company, trading as AMBX, secured $150M in financing. Neridronate has FDA designations and is in Phase 3 trials, with results expected in 2028. The merger values Ambros at $500M and Werewolf at $47.5M, with a planned Q1 2027 close. HOWL shares surged 1431.19% in pre-market trading.